NovoSeven coagulation factor VIIa (recombinant) for prevention and control of bleeding in patients without hemophilia

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
NovoSeven coagulation factor VIIa (recombinant) for prevention and control of bleeding in patients without hemophilia. Lansdale: HAYES, Inc.. Directory Publication. 2011

Authors' objectives
NovoSeven® (rFVIIa; Novo Nordisk Inc.) is a commercially produced recombinant human clotting factor VIIa that acts as a local hemostatic agent at the site of ruptured blood vessels to prevent further bleeding and minimize hematoma growth. It is approved for use in patients with hemophilia and other hematologic disorders. Hemostatic effects are localized because tissue factor and activated platelets are only present at the site of blood vessel rupture. NovoSeven is used in nonhemophiliac patients to achieve adequate control of massive bleeding if conventional measures fail. NovoSeven may also be used prophylactically prior to surgical interventions that carry a high risk of excessive bleeding.

Final publication URL
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=12232

Indexing Status
Subject indexing assigned by CRD

MeSH
Blood Coagulation Factor Inhibitors; Factor VIIa; Hemophilia A; Hemorrhages; Recombinant Proteins

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com

AccessionNumber
32011000899

Date abstract record published
15/06/2011